The impact of CD24 antibody treatment in MCL was further evaluated using a panel of seven cell lines with different CD24 expression levels (Figure 1C), ranging from high (CD24high; UPN-1, HBL-2), moderate (CD24mod; JeKo-1) to low (CD24low; Rec-1, Granta-519, Maver-1, Z-138). This evidence concerns the gene CD24 and mantle cell lymphoma.